News headlines about Allscripts Healthcare Solutions (NASDAQ:MDRX) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Allscripts Healthcare Solutions earned a news impact score of 0.20 on Accern’s scale. Accern also gave media stories about the software maker an impact score of 46.2346706055454 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
- Falling Earnings Visibility Keep Allscripts Healthcare Solutions (MDRX) a Sell (investorplace.com)
- Pleasing Stocks: Allscripts Healthcare Solutions, Inc., (NASDAQ: MDRX), Zogenix, Inc., (NASDAQ: ZGNX … – Stocks In The News (press release) (tradingnewsnow.com)
- Stocks In Focus:: Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), 3D Systems Corporation (NYSE:DDD … – The Stock Street (press release) (thestreetpoint.com)
- Allscripts Healthcare Solutions, Inc. (MDRX) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Allscripts Healthcare Solutions, Inc. (MDRX) Short Interest Update (americanbankingnews.com)
Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up $0.38 on Thursday, reaching $13.14. The company’s stock had a trading volume of 1,690,906 shares, compared to its average volume of 2,346,123. Allscripts Healthcare Solutions has a 12-month low of $10.19 and a 12-month high of $14.45. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.98 and a current ratio of 0.98. The firm has a market capitalization of $2,370.00, a price-to-earnings ratio of 29.63, a PEG ratio of 2.27 and a beta of 1.34.
MDRX has been the topic of a number of recent analyst reports. Piper Jaffray Companies reiterated a “hold” rating and issued a $14.00 target price on shares of Allscripts Healthcare Solutions in a research report on Friday, July 21st. Maxim Group restated a “buy” rating and set a $16.00 price target on shares of Allscripts Healthcare Solutions in a report on Friday, August 4th. Morgan Stanley boosted their price target on Allscripts Healthcare Solutions from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Monday, August 7th. Citigroup Inc. boosted their price target on Allscripts Healthcare Solutions from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, August 7th. Finally, Zacks Investment Research upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $15.06.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://ledgergazette.com/2017/11/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-allscripts-healthcare-solutions-mdrx-share-price.html.
In other Allscripts Healthcare Solutions news, CEO Paul Black sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $13.52, for a total value of $202,800.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Brian Farley sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $13.52, for a total value of $67,600.00. Following the completion of the transaction, the executive vice president now directly owns 196,607 shares in the company, valued at $2,658,126.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,000 shares of company stock worth $473,800. Insiders own 0.75% of the company’s stock.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.